AARD
NASDAQ · Pharmaceuticals
Aardvark Therapeutics Inc
$4.07
-0.83 (-16.94%)
Financial Highlights (FY 2025)
Revenue
44.31M
Net Income
12.13M
Gross Margin
52.9%
Profit Margin
27.4%
Rev Growth
-1.8%
D/E Ratio
0.60
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 52.9% | 52.9% | 52.9% |
| Operating Margin | 30.1% | 33.3% | 34.3% |
| Profit Margin | 27.4% | 23.9% | 24.7% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 44.31M | 42.19M | 44.45M |
| Gross Profit | 23.42M | 22.30M | 23.50M |
| Operating Income | 13.35M | 14.05M | 15.24M |
| Net Income | 12.13M | 10.07M | 10.99M |
| Gross Margin | 52.9% | 52.9% | 52.9% |
| Operating Margin | 30.1% | 33.3% | 34.3% |
| Profit Margin | 27.4% | 23.9% | 24.7% |
| Rev Growth | -1.8% | +11.1% | +14.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 132.58M | 124.67M | 110.52M |
| Total Equity | 221.13M | 200.64M | 224.89M |
| D/E Ratio | 0.60 | 0.62 | 0.49 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 17.61M | 17.80M | 18.44M |
| Free Cash Flow | 9.43M | 7.96M | 8.12M |